Advances in neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma: An invited commentary  

作　　者：Ruyu Han Peipei Song Wei Tang Tianqiang Song Lu Chen 

机构地区：[1]Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine,Tianjin Key Laboratory of Digestive Cancer,Tianjin’s Clinical Research Center for Cancer,Tianjin,China [2]Department of Hepatobiliary Cancer,Liver Cancer Research Center,Tianjin Medical University Cancer Institute and Hospital,Tianjin,China [3]National Center for Global Health and Medicine,Tokyo,Japan

出　　处：《Oncology and Translational Medicine》2025年第1期1-4,共4页肿瘤学与转化医学(英文版)

基　　金：supported by the National Natural Science Foundation of China(grants 82373365 and 82173317);the Tianjin Key Medical Discipline Construction Project(TJYXZDXK-009A).

摘　　要：Intrahepatic cholangiocarcinoma(ICC)poses a significant threat to human health owing to its high malignancy rate and poor prognosis.Sur-gery is the most effective treatment option for ICC.However,the prognosis remains unfavorable even after surgical resection.Therefore,neo-adjuvant therapy has emerged as a potential treatment option for patients with ICC.Neoadjuvant therapy can improve patient prognosis by reducing the tumor size and eliminating tiny lesions that are not visible to the naked eye.Nevertheless,specific treatment options for neoad-juvant therapy are unavailable.This review summarizes the studies on neoadjuvant therapy for ICC in the last decade,including chemotherapy,radiotherapy,interventional therapy,targeted therapy,and immunotherapy,with the aim of providing suggestions for the selection of clinical treatment options for patients with ICC.Current reports suggest that chemotherapy is the most effective neoadjuvant treatment option.How-ever,radiotherapy and interventional therapies require further investigation to obtain conclusive recommendations.Although targeted thera-pies and immunotherapies have been studied less extensively,several ongoing clinical trials are investigating these promising approaches.

关 键 词：Intrahepatic cholangiocarcinoma Resectable Neoadjuvant therapy 

分 类 号：R73[医药卫生—肿瘤]